Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice

• Nishikawa, Toshio

• Takaoka, Munenori

• Ohara, Toshiaki

• Tomono, Yasuko

• Hao, Huifang

• Bao, Xiaohong

• Fukazawa, Takuya

• Wang, Zhigang

• Sakurama, Kazufumi

• Fujiwara, Yasuhiro

• Motoki, Takayuki

• Shirakawa, Yasuhiro

• Yamatsuji, Tomoki

• Tanaka, Noriaki

• Fujiwara, Toshiyoshi

• Naomoto, Yoshio

抄録

Esophageal squamous cell carcinoma (ESCC) remains one of the most aggressive cancers with poor prognosis regardless of a several reports that indicate a better therapeutic efficacy using some new chemotherapeutic agents. Recent drug development has contributed to an improved specificity to suppress mTOR activity by which many types of malignancies can be explosively progressed. Temsirolimus (CCI-779, TricelTM) is one of recently synthesized analogs of rapamycin and has provided better outcomes for patients with renal cell carcinoma. In this study, we experimentally evaluated an efficacy of targeting mTOR by temsirolimus for ESCC treatment, with an assessment of its survival advantage using an advanced ESCC animal model. First, we confirmed that the expression of phosphorylated mTOR was increased in 46 of 58 clinical ESCC tumor tissues (79.3%) and appeared to get strengthened with tumor progression. All of ESCC cell lines used in this study revealed an increase of mTOR phosphorylation, accompanied with the upregulation of hypoxia inducible factor-I alpha (HIF-1 alpha), one of the critical effectors regulated by mTOR. Temsirolimus treatment apparently suppressed the activation of mTOR and its downstream effectors, resulting in the reduced ability of ESCC cell proliferation. Finally, the weekly administration of temsirolimus significantly diminished the size of subcutaneous tumors (vehicle, 3261.6 +/- 722.0; temsirolimus, 599.2 +/- 122.9; p = 0.007) in nude mice and effectively prolonged orthotopic esophageal cancer-bearing mice (median survival periods: control, 31 d; temsirolimus, 43 d; p = 0.0024). These data suggests that targeting mTOR by temsirolimus may become a therapeutic alternative for esophageal cancer, with a contribution to a better outcome.

収録刊行物

• Cancer Biology & Therapy

  Cancer Biology & Therapy 14 (3), 230-236, 2013-03

  Landes Bioscience

キーワード

• temsirolimus
• esophageal cancer
• mTOR
• prolonged survival
• molecular-targeted therapy

詳細情報

• CRID: 1050283687764297600
• NII論文ID: 120005324790
• ISSN: 15384047
• Web Site: https://ousar.lib.okayama-u.ac.jp/51441
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • CiNii Articles